Genomic Biotech Peer Comparison

BSE: 539206

₹30.00

₹1.13 (3.91%)

As on 31-Aug-2026IST

Market cap

₹9 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

436.4

P/B Ratio

2.3

Div. Yield

0 %

Edit

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Market cap (₹ Cr)	9	2,799	271	229	42
Revenue (₹ Cr)	0	2,901	138	85	55
Net Profit (₹ Cr)	0.02	16.16	-9.39	12.82	-2.86
Net Margin (%)	9.72	0.55	-6.66	6.38	-5.15
RoE (%)	0.53	0.29	-9.20	20.84	-16.06
Price to Earnings	436.36	173.23	--	17.85	--
Price-To-Book	2.32	0.42	2.87	7.14	0.45

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Operating Revenue	0.22	2,901.49	137.73	84.56	55.10
Total Income	0.22	2,950.84	141.01	92.53	55.46
Total Expenditure	0.18	2,416.46	140.53	86.29	34.09
EBITDA	0.04	485.03	-2.80	-1.73	21.01
Depreciation	0.00	348.02	8.36	0.01	11.51
EBIT	0.03	137.01	-11.16	-1.74	9.50
Interest	0.00	168.51	3.32	0.18	5.58
Other Income	0.00	49.35	3.29	7.97	0.36
Exceptional Items	0.00	-2.84	0.00	0.00	-0.61
Profit before Tax	0.03	15.01	-11.19	6.06	3.67
Provision for Tax	0.01	-1.15	-1.80	0.16	6.53
Profit after Tax	0.02	16.16	-9.39	5.90	-2.86

Liabilities (₹ Cr)

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Shareholder's Funds	3.93	6,676.90	92.39	31.00	93.16
Minority Interest	0.00	0.00	0.49	0.00	0.00
Non-Current Liabilities	0.00	2,929.36	29.81	0.00	55.04
Current Liabilities	0.32	2,317.05	53.90	5.24	30.23
Total Liabilities	4.36	9,986.90	176.20	36.48	143.23

Assets (₹ Cr)

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Non-Current Assets	1.55	8,580.12	88.99	0.00	149.74
Current Assets	2.70	2,842.10	63.28	23.77	28.42
Total Assets	4.36	9,986.90	176.20	36.48	143.23
Total Debt*	0.00	2,083.91	38.00	0.00	54.03
Net Current Assets	2.38	525.05	9.38	18.53	-1.82
Contingent Liabilities	--	423.42	26.88	74.49	--

Cashflow (₹ Cr)

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Cash From Operating Activities	0.03	375.23	1.90	-16.37	11.83
Cash Flow from Investing Activities	0.01	-192.21	-11.80	22.21	-15.84
Cash from Financing Activities	--	-102.09	5.29	-3.24	3.90
Net Cash Inflow / Outflow	0.04	80.93	-4.60	2.60	-0.11

Ratios

Profitability Ratios

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
ROCE (%)	11.87	2.31	10.01	13.63	12.63
ROE (%)	0.53	0.29	-9.20	20.84	-16.06
ROA (%)	0.49	0.15	-5.35	16.23	-1.78
EBIT Margin (%)	14.35	4.72	-8.10	-2.05	17.24
Net Margin (%)	9.72	0.55	-6.66	6.38	-5.15
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Revenue Growth (%)	-72.27	0.20	-2.60	-100.00	12.34
EBIT Growth (%)	-90.43	-50.39	-203.38	67.89	-22.16
Net Profit Growth (%)	-91.46	-84.49	-222.82	81.10	-133.81
EPS Growth (%)	-91.46	-85.24	-218.89	81.10	-230.45
Book Value Growth (%)	10.05	3.63	76.48	331.34	30.20

Valuation Ratios

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Price / Earnings	436.36	150.41	-29.98	38.78	-2.73
Price / Book Value	2.32	0.42	2.87	7.14	0.45
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	260.52	8.97	-113.68	-130.23	4.49
Market Cap (₹ Cr)	17.90	3,411.88	360.30	--	58.31

Solvency Ratios

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Debt to Equity	0.00	0.23	0.25	0.00	0.50
Short term debt to equity ratio	--	0.11	0.14	--	0.15
Current Ratio	8.40	1.23	1.17	4.54	0.94
Quick Ratio	7.52	0.79	0.92	4.54	0.67
Interest Coverage	2,845.31	1.09	-2.37	35.64	1.66

Operating Efficiency Ratios

	Genomic Biotech	Dishman Carbogen	Lyka Labs	Take Solutions	Vivo Bio Tech
Debtors to sales (%)	1,073.15	23.19	25.44	0.26	21.32
Asset Turnover	0.05	0.26	0.79	2.33	0.34
Receivable days	1,026.01	77.38	92.33	--	90.11
Inventory Days	122.93	120.02	29.04	--	64.77
Payable days	554.30	172.74	88.82	--	64.32
Cash Conversion Cycle	594.64	24.66	32.55	--	90.56

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly